J. Pers. Med. 2012, 2(3), 71-76; doi:10.3390/jpm2030071
Case Report

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report

Steven R. Schuster 1,* email, Barbara A. Pockaj 2 email, Mary R. Bothe 1 email, Paru S. David 3 email and Donald W. Northfelt 1 email
1 Division of Hematology and Oncology, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA 2 Department of Surgery, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA 3 Department of Womens Health, Mayo Clinic Arizona, 13400 E Shea Blvd., Scottsdale, AZ 85259, USA
* Author to whom correspondence should be addressed.
Received: 16 August 2012 / Accepted: 4 September 2012 / Published: 10 September 2012
PDF Full-text Download PDF Full-Text [647 KB, uploaded 10 September 2012 14:51 CEST]
Abstract: Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient’s decision. In light of this case, we discuss the benefits and limitations of these tools.
Keywords: breast cancer; genomic profiling; medical decision-making; Oncotype DX; chemotherapy; personalized medicine

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Schuster, S.R.; Pockaj, B.A.; Bothe, M.R.; David, P.S.; Northfelt, D.W. Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report. J. Pers. Med. 2012, 2, 71-76.

AMA Style

Schuster SR, Pockaj BA, Bothe MR, David PS, Northfelt DW. Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report. Journal of Personalized Medicine. 2012; 2(3):71-76.

Chicago/Turabian Style

Schuster, Steven R.; Pockaj, Barbara A.; Bothe, Mary R.; David, Paru S.; Northfelt, Donald W. 2012. "Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report." J. Pers. Med. 2, no. 3: 71-76.

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert